Our projects
Brilliant scientists, powerful collaborations. We find and fund projects that are ripe for impacting Duchenne now.Access to best care and new treatments
We are proud to have invested in research and care improvement that is already making a difference to those living with Duchenne, and their families. Click below to learn more.
Duchenne Care UK: Best Care For All
Duchenne Care UK is a national initiative funded by Duchenne UK, Duchenne Research Fund and Joining Jack to make care better for everyone with Duchenne, across the UK, at all stages of life.
Duchenne Care UK Psychosocial
We are focused on improving provision and access to the best psychological and psychiatric support, as well as best practice in schools for neurodivergent children with Duchenne.
Vamorolone
We are proud to have been a Phase I funder of vamorolone, an alternative steroid treatment for Duchenne, which is now approved in the UK, US and EU. Following a NICE approval process, it is now available on the NHS.
Gene therapy progress
The underlying cause of Duchenne is the lack of dystrophin produced by the dystrophin gene. While there are some promising new treatments that help to slow progression or alleviate symptoms, most treatments do not tackle this underlying genetic mutation. We have funded a range of gene therapies which aim to correct the mutation in the dystrophin gene. There has been promising progress in this area and a number of gene therapies have reached the clinical trial stage. Read below to learn more about the research we have funded.
Gene therapy for Duchenne
Solid Biosciences’ ground-breaking gene therapy programme for Duchenne.
CRISPR for Duchenne muscular dystrophy
A novel gene editing approach to correct the mutated dystrophin gene.
Gene therapy for Becker
A microdystrophin gene therapy approach for Becker muscular dystrophy.
Grants and awards for clinicians and facilities
The DRF has invested in a diverse range of pre-clinical and clinical research programmes to tackle the complex nature of Duchenne muscular dystrophy: from anti-inflammatory treatments, to novel methods of delivering gene therapies into the body, to ways to adapt the immune system to better receive treatments, as well as novel biomarkers – ways to measure which treatments are working and how quickly. Click below to learn more about what we have funded.
Activity monitoring biomarker
KINEDMD: Wearable sensor technology to monitor Duchenne patients’ activity.
Combating immunity to AAV
Ensuring as many patients as possible can benefit from gene therapy.
Blood-based biomarker
Measuring disease progression and response to new treatments.
Non-viral delivery
A next-generation gene therapy delivery approach.
Non-invasive imaging biomarker
Reducing biopsies and improving dystrophin analysis in Duchenne boys.
SMT C1100
Increasing utrophin to compensate for dystrophin.
Ringo
Dystrophic dogs provide insights into Duchenne research.
Neurobehavioural issues in Duchenne
Tackling learning, behaviour, depression and anxiety.
LTBP4
This project focuses on targeting inflammation and fibrosis – two key challenges in Duchenne.
HT-100
Pre-clinical research for drug to target muscle fibrosis.
Our commitment
Our scientific advisory board comprises leading minds in the field: Professor Ronald Cohn, Dr Kevin Campbell, Professor Madeleine Durbeej-Hjalt and Dr James Dowling together with our Honorary Scientific Patron Professor Victor Dubowitz. Read more about their work here. Please contact research [at] duchenne.org.uk for more information about applications.
Our mission
Our impact
Your help
Your generosity has funded millions of pounds worth of ground-breaking research.
And there is still work to do.